Lead Product(s) : Savolitinib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
HUTCHMED Finishes Enrollment for Savolitinib Gastric Cancer Phase 2 Trial
Details : HMPL-504 (savolitinib) is an oral, potent, and highly selective MET tyrosine kinase inhibitor, being developed for gastric cancer.
Product Name : HMPL-504
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 21, 2025
Lead Product(s) : Savolitinib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
HUTCHMED Completes Phase 2 Enrollment for Fanregratinib in Cholangiocarcinoma
Details : HMPL-453 (fanregratinib) is a novel, highly selective and potent inhibitor targeting FGFR 1, 2 and 3. It is being evaluated for intrahepatic cholangiocarcinoma.
Product Name : HMPL-453
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 06, 2025
Lead Product(s) : Osimertinib Mesylate,Savolitinib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
TAGRISSO® and ORPATHYS® Show High Response in MET-Positive Lung Cancer in SAVANNAH Study
Details : Tagrisso (osimertinib) is being evaluated in the mid-stage clinical trial studies in combination with Orpathys (savolitinib) for EFGR-mutated non-small cell lung cancer.
Product Name : Tagrisso
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 16, 2024
Lead Product(s) : Osimertinib Mesylate,Savolitinib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tazemetostat
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
HUTCHMED Receives NDA Acceptance & Priority Review for Tazemetostat in Follicular Lymphoma
Details : Tazverik (tazemetostat) is a first-in-class methyltransferase inhibitor of EZH2, which is being evaluated for the treatment of relapsed or refractory follicular lymphoma.
Product Name : Tazverik
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 07, 2024
Lead Product(s) : Tazemetostat
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fruquintinib,Sintilimab
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Innovent Biologics
Deal Size : Inapplicable
Deal Type : Inapplicable
HUTCHMED and Innovent Announce NDA Acceptance for Fruquintinib in China
Details : Fruzaqla (fruquintinib) is a selective oral VEGFR inhibitor blocking tumor angiogenesis. It is being investigated with sintilimab (PD-1 inhibitor) for treating advanced endometrial cancer.
Product Name : Elunate
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 04, 2024
Lead Product(s) : Fruquintinib,Sintilimab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Innovent Biologics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tazemetostat
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TAZVERIK® (tazemetostat) is a methyltransferase inhibitor indicated in the United States for the treatment of relapsed/refractory follicular lymphoma.
Product Name : Tazverik
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 09, 2023
Lead Product(s) : Tazemetostat
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Savolitinib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
HUTCHMED Receives Breakthrough Therapy Designation in China for Savolitinib for Gastric Cancer
Details : Orpathys (savolitinib), is an oral, potent and highly selective MET tyrosine kinase inhibitor that has demonstrated clinical activity in advanced solid tumors.
Product Name : Orpathys
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 28, 2023
Lead Product(s) : Savolitinib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : HMPL-453 is a novel, highly selective and potent inhibitor targeting FGFR 1, 2 and 3. Aberrant FGFR signaling has been found to be a driving force in tumor growth (through tissue growth and repair), promotion of angiogenesis and resistance to anti-tumor ...
Product Name : HMPL-453
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 04, 2023
Lead Product(s) : Amdizalisib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : HMPL-689 (amdizalisib) is a novel, selective and potent oral inhibitor targeting the isoform PI3K delta. PI3K delta is a target for drugs that aim to prevent or treat hematologic cancer.
Product Name : HMPL-689
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 27, 2023
Lead Product(s) : Amdizalisib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Savolitinib,Osimertinib Mesylate
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Savolitinib (ORPATHYS), is an oral, potent, and highly selective MET TKI that has demonstrated clinical activity in advanced solid tumors, blocks atypical activation of MET receptor tyrosine kinase pathway.
Product Name : Orpathys
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 13, 2022
Lead Product(s) : Savolitinib,Osimertinib Mesylate
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable